Warum in die Ferne schweifen, wenn das Gute sticht so nah?
https://x.com/2StefanMoore/status/1992787544489234571[*quote*]
Stefan Moore ★ @2StefanMoore
In a remarkable scientific discovery, researchers have shown that bee venom can completely destroy aggressive #BreastCancer cells, including triple negative & HER2 positive subtypes in less than 60 minutes.
The key ingredient responsible is melittin, a small peptide in the venom. Melittin punches holes in the membranes of cancer cells, causing them to burst & die almost instantly. What makes this especially promising is its precision: at the concentrations tested, melittin leaves healthy cells virtually unharmed bc cancer cell membranes have different properties that make them far more vulnerable to the attack.
This has been published in 2020 by scientists at the Harry Perkins Institute of Medical Research in Western Australia & later confirmed in follow-up studies that the venom (or synthetic melittin) achieved 100% cancer cell death in lab dishes within one hour. When tested in mice, combining melittin with existing chemotherapy drugs dramatically shrank tumors with minimal side effects.
While this breakthrough is still in the preclinical stage, no human treatments using bee venom exist yet. Researchers are now developing ways to safely deliver melittin directly to tumors in the body (for example, by attaching it to tiny nanoparticles). If successful, it could lead to a new generation of targeted cancer therapies that are faster acting & far less toxic than traditional chemotherapy.
Once again, nature, this time in the form of a honeybee’s sting is showing us powerful new ways to fight one of humanity’s deadliest diseases.
Image
3:49 AM · Nov 24, 2025
3,487 Views
[*/quote*]
[*quote*]
Harry Perkins Institute of Medical Research
Honeybee venom kills breast cancer cellsLab News & Events September 2, 2020
Venom from honeybees found to kill aggressive breast cancer cells – Australian research published in Nature Precision Oncology
Honeybee venom induces cancer cell death in hard to treat triple-negative breast cancer with minimal effect on healthy cells.
Using the venom from 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, Dr Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia, tested the effect of the venom on the clinical subtypes of breast cancer, including triple-negative breast cancer, which has limited treatment options.
Results published in the prestigious international journal NPJ Nature Precision Oncology revealed that honeybee venom rapidly destroyed triple-negative breast cancer and HER2-enriched breast cancer cells.
Dr Duffy said the aim of the research was to investigate the anti-cancer properties of honeybee venom, and a component compound, melittin, on different types of breast cancer cells.
“No-one had previously compared the effects of honeybee venom or melittin across all of the different subtypes of breast cancer and normal cells.
“We tested honeybee venom on normal breast cells, and cells from the clinical subtypes of breast cancer: hormone receptor positive, HER2-enriched, and triple-negative breast cancer.
“We tested a very small, positively charged peptide in honeybee venom called melittin, which we could reproduce synthetically, and found that the synthetic product mirrored the majority of the anti-cancer effects of honeybee venom,” Dr Duffy said.
“We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells.
“The venom was extremely potent,” Dr Duffy said.
A specific concentration of honeybee venom can induce 100% cancer cell death, while having minimal effects on normal cells.
“We found that melittin can completely destroy cancer cell membranes within 60 minutes.”
Melittin in honeybee venom also had another remarkable effect; within 20 minutes, melittin was able to substantially reduce the chemical messages of cancer cells that are essential to cancer cell growth and cell division.
“We looked at how honeybee venom and melittin affect the cancer signalling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signalling pathways were shut down.
“Melittin modulated the signalling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer,” she said.
Western Australia’s Chief Scientist Professor Peter Klinken said “This is an incredibly exciting observation that melittin, a major component of honeybee venom, can suppress the growth of deadly breast cancer cells, particularly triple-negative breast cancer.
“Significantly, this study demonstrates how melittin interferes with signalling pathways within breast cancer cells to reduce cell replication. It provides another wonderful example of where compounds in nature can be used to treat human diseases”, he said.
Dr Duffy also tested to see if melittin could be used with existing chemotherapy drugs as it forms pores, or holes, in breast cancer cell membranes, potentially enabling the entry of other treatments into the cancer cell to enhance cell death.
“We found that melittin can be used with small molecules or chemotherapies, such as docetaxel, to treat highly-aggressive types of breast cancer. The combination of melittin and docetaxel was extremely efficient in reducing tumour growth in mice.”
Dr Duffy’s research was conducted as part of her PhD undertaken at Perth’s Harry Perkins Institute of Medical Research at the Cancer Epigenetics laboratory overseen by Associate Professor Pilar Blancafort.
“I began with collecting Perth honeybee venom. Perth bees are some of the healthiest in the world.
“The bees were put to sleep with carbon dioxide and kept on ice before the venom barb was pulled out from the abdomen of the bee and the venom extracted by careful dissection,” she said.
While there are 20,000 species of bees, Dr Duffy wanted to compare the effects of Perth honeybee venom to other honeybee populations in Ireland and England, as well as to the venom of bumblebees.
“I found that the European honeybee in Australia, Ireland and England produced almost identical effects in breast cancer compared to normal cells. However, bumblebee venom was unable to induce cell death even at very high concentrations.
One of the first reports of the effects of bee venom was published in Nature in 1950, where the venom reduced the growth of tumours in plants. However, Dr Duffy said it was only in the past two decades that interest grew substantially into the effects of honeybee venom on different cancers.
In the future, studies will be required to formally assess the optimum method of delivery of melittin, as well as toxicities and maximum tolerated doses.
Fast Facts
Breast cancer is the most commonly occurring cancer in women worldwide[1]
It is the second most common cause of death from cancer among females[2]
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancers[3]
There are currently no clinically effective targeted treatments for TNBC
[1]
https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics[2]
https://canceraustralia.gov.au/affected-cancer/cancer-types/breast-cancer/statistics[3]
https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.htmlPerkins North
QEII Medical Centre
6 Verdun St
Nedlands WA 6009
Get in touch
Ph: +61 8 6151 0700
E: info@perkins.org.au
Perkins South
Fiona Stanley Hospital
5 Robin Warren Dr
Murdoch WA 6150
ABN 16 823 190 402
All donations of $2 and over are tax deductible in Australia.
Perkins is registered with the Australian Taxation Office as a Deductible Gift Recipient (DGR): Charitable Fundraising Authority No DGR CC20761
The Harry Perkins Institute of Medical Research recognises Australia’s first healers and scientists, the Aboriginal and Torres Strait Islander peoples. We acknowledge the Whadjuk people of the Noongar nation, the Traditional Custodians of the lands where we live and work, and pay respects to their elders past and present.
© 2025 Harry Perkins Institute of Medical Research
[*/quote*]
